extract: 2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021
Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>
This commit is contained in:
Teleo Agents
parent
c8406c8688
commit
99a99e75af
3 changed files with 61 additions and 1 deletions
|
|
@ -57,6 +57,12 @@ OBBBA work requirements threaten to remove ~10M from Medicaid coverage precisely
|
|||
|
||||
---
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021]] | Added: 2026-03-29*
|
||||
|
||||
PCSK9 inhibitors show sociodemographic disparities in utilization independent of clinical indication. JAHA 2021 adoption study found Black and Hispanic ASCVD patients had lower PCSK9 utilization than white patients at all income levels. This pattern parallels GLP-1 discontinuation disparities, suggesting affordability/access barriers create systematic underutilization in lower-income and minority populations across multiple high-cost cardiovascular/metabolic drug classes.
|
||||
|
||||
|
||||
Relevant Notes:
|
||||
- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
|
||||
|
|
|
|||
|
|
@ -0,0 +1,39 @@
|
|||
---
|
||||
type: claim
|
||||
domain: health
|
||||
description: "Four years post-FDA approval, PCSK9 inhibitors reached only 2.5% of eligible patients despite RCT-proven efficacy, with 50% of prescriptions rejected by payers—the highest barrier rate of any major cardiovascular drug class"
|
||||
confidence: likely
|
||||
source: "Circulation: Cardiovascular Quality and Outcomes 2024, large US claims database 2015-2021"
|
||||
created: 2026-03-29
|
||||
attribution:
|
||||
extractor:
|
||||
- handle: "vida"
|
||||
sourcer:
|
||||
- handle: "circulation:-cardiovascular-quality-and-outcomes"
|
||||
context: "Circulation: Cardiovascular Quality and Outcomes 2024, large US claims database 2015-2021"
|
||||
---
|
||||
|
||||
# PCSK9 inhibitors achieved only 1-2.5% penetration among eligible ASCVD patients despite proven 15% MACE reduction demonstrating that the pharmacological ceiling is access-mediated not drug-class-limited
|
||||
|
||||
PCSK9 inhibitors (evolocumab, alirocumab) demonstrated 15% MACE reduction in FOURIER (2017) and ODYSSEY OUTCOMES (2018) trials on top of statin therapy—proven individual efficacy with FDA approval and ACC/AHA guideline endorsement. Yet population penetration remained catastrophically low: only 0.9% of ASCVD patients on statin therapy filled a PCSK9 prescription overall, rising from 0.05% in Q3 2015 to only 2.5% by Q2 2019. Among hospitalized ASCVD patients (2020-2022)—an ideal prescribing opportunity—only 1.3% received PCSK9 inhibitors.
|
||||
|
||||
The barrier is not clinical but financial: 49.93% of PCSK9 prescriptions written were never filled (compared to 68-84% fill rates for other branded cardiometabolic therapies). Amgen reported 83% of PCSK9 claims initially rejected, with 57% ultimately rejected—the highest rejection rate of any cardiovascular drug class. Commercial insurance final rejection was 69.5%; Medicare 42.3%.
|
||||
|
||||
Critically, the 2018 price reduction (from ~$14,000/year to ~$5,800/year) improved adherence among patients who accessed the drug but did NOT produce population-level penetration increases. This demonstrates the ceiling is structural (payer gatekeeping) not merely price-sensitive.
|
||||
|
||||
This is direct quantitative evidence that the 'pharmacological ceiling' in US cardiovascular mortality is access-mediated, not a biological limitation of drug classes. The same pattern appears with GLP-1 agonists: individual efficacy proven, population penetration blocked by pricing/access barriers.
|
||||
|
||||
---
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: 2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021 | Added: 2026-03-29*
|
||||
|
||||
Large US claims database (2015-2021) shows PCSK9 penetration rose from 0.05% in Q3 2015 to only 2.5% by Q2 2019 — four years post-FDA approval. Overall penetration: 0.9% of ASCVD patients on statin therapy filled a PCSK9 prescription (126,419 patients). Only 49.93% of written PCSK9 prescriptions were successfully filled (vs 68-84% for comparable branded cardiometabolic therapies). Hospitalized ASCVD patients (2020-2022) received PCSK9 inhibitors at only 1.3% rate despite hospitalization providing ideal prescribing opportunity. Commercial insurance rejection: 69.5%; Medicare: 42.3%. The 2018 price reduction (from ~$14,000/year to ~$5,800/year) improved adherence in commercially insured patients but did NOT produce population-level penetration increase.
|
||||
|
||||
|
||||
Relevant Notes:
|
||||
- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
- [[lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence]]
|
||||
|
||||
Topics:
|
||||
- [[_map]]
|
||||
|
|
@ -7,9 +7,13 @@ date: 2024-01-01
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: research-paper
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [PCSK9, cardiovascular, access-barriers, pharmacological-ceiling, utilization, ASCVD, prior-authorization, belief-1]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-29
|
||||
enrichments_applied: ["pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -44,3 +48,14 @@ Published in *Circulation: Cardiovascular Quality and Outcomes*, 2024. Large US
|
|||
PRIMARY CONNECTION: [[Session 13 claim candidate: access-mediated pharmacological ceiling]]; GLP-1 access archives (India generic vs. US patent); OBBBA coverage loss
|
||||
WHY ARCHIVED: Quantitative anchor for access-mediated ceiling hypothesis — converts the "probably <5%" estimate from Session 13 into a documented 1–2.5% figure with specific primary source
|
||||
EXTRACTION HINT: Pair with SELECT trial CVD data and GLP-1 access barriers to build the complete "access-mediated pharmacological ceiling" claim. The pattern spans two drug generations (PCSK9 2015-2022, GLP-1 2024-present) — making it a structural pattern, not a one-time anomaly.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- PCSK9 inhibitors achieved 15% MACE reduction in FOURIER (2017) and ODYSSEY OUTCOMES (2018) trials
|
||||
- PCSK9 inhibitor price reduced from ~$14,000/year to ~$5,800/year in 2018
|
||||
- Only 0.9% of ASCVD patients on statin/PCSK9 therapy filled a PCSK9 inhibitor prescription (126,419 patients in sample)
|
||||
- PCSK9 penetration rose from 0.05% in Q3 2015 to 2.5% by Q2 2019
|
||||
- 49.93% of PCSK9 prescriptions written were successfully filled (vs 68-84% for other branded cardiometabolic therapies)
|
||||
- Only 1.3% of hospitalized ASCVD patients (2020-2022) received PCSK9 inhibitors
|
||||
- 83% of PCSK9 prescription claims initially rejected; 57% ultimately rejected (Amgen 2017)
|
||||
- Commercial insurance final rejection: 69.5%; Medicare: 42.3%
|
||||
|
|
|
|||
Loading…
Reference in a new issue